Yarrow Bioscience Inc (NASDAQ:YARW) — Market Cap & Net Worth
Market Cap & Net Worth: Yarrow Bioscience Inc (YARW)
Yarrow Bioscience Inc (NASDAQ:YARW) has a market capitalization of $52.62 Million ($52.62 Million) as of October 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21722 globally and #4829 in its home market, demonstrating a -16.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yarrow Bioscience Inc's stock price $19.71 by its total outstanding shares 2669788 (2.67 Million).
Yarrow Bioscience Inc Market Cap History: 2026 to 2026
Yarrow Bioscience Inc's market capitalization history from 2026 to 2026. Data shows growth from $52.62 Million to $52.62 Million (0.00% CAGR). Check Yarrow Bioscience Inc share price for real-time trading data and today's change.
Yarrow Bioscience Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yarrow Bioscience Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Yarrow Bioscience Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of YARW by Market Capitalization
Companies near Yarrow Bioscience Inc in the global market cap rankings as of October 10, 2026. See debt-free asset ratio of Yarrow Bioscience Inc to understand what proportion of total assets are financed by equity.
Key companies related to Yarrow Bioscience Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Yarrow Bioscience Inc Historical Marketcap From 2026 to 2026
Between 2026 and today, Yarrow Bioscience Inc's market cap moved from $52.62 Million to $ 52.62 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $52.62 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Yarrow Bioscience Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.62 Million USD |
| MoneyControl | $52.62 Million USD |
| MarketWatch | $52.62 Million USD |
| marketcap.company | $52.62 Million USD |
| Reuters | $52.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based i… Read more